Author: Beghi, Ettore; Helbok, Raimund; Crean, Michael; Chou, Sherry Hsiangâ€Yi; McNett, Molly; Moro, Elena; Bassetti, Claudio
Title: The EAN COVIDâ€19 registry (ENERGY): An international instrument for surveillance of neurological complications in patients with COVIDâ€19 Cord-id: 5z080j8s Document date: 2020_11_21
ID: 5z080j8s
Snippet: The COVIDâ€19 pandemic is a global public health issue. Neurological complications have been reported in up to oneâ€third of affected cases, but their distribution varies significantly in terms of prevalence, incidence and phenotypical characteristics. Variability can be mostly explained by the differing sources of cases (hospital vs. communityâ€based), the accuracy of the diagnostic approach, and the interpretation of the patients’ complaints. Moreover, after recovering, patients can still
Document: The COVIDâ€19 pandemic is a global public health issue. Neurological complications have been reported in up to oneâ€third of affected cases, but their distribution varies significantly in terms of prevalence, incidence and phenotypical characteristics. Variability can be mostly explained by the differing sources of cases (hospital vs. communityâ€based), the accuracy of the diagnostic approach, and the interpretation of the patients’ complaints. Moreover, after recovering, patients can still experience neurological symptoms. To obtain a more precise picture of the neurological manifestations and outcome of the COVIDâ€19 infection, an international registry (ENERGY) has been created by the European Academy of Neurology (EAN) in collaboration with European national neurological societies and the Neurocritical Care Society and Research Network (NCRN). ENERGY can be implemented as a standâ€alone instrument for patients with suspected or confirmed COVIDâ€19 patients AND neurological findings or as an addendum to an existing registry not targeting neurologic symptoms. Data are also collected to study the impact of neurological symptoms and neurological complications on outcomes. The variables included in the registry have been selected in the interest of most countries, to favour pooling with data from other sources, and to facilitate data collection even in resourceâ€poor countries. Included are adults with suspected or confirmed COVIDâ€19 infection, ascertained through neurological consultation, and providing informed consent. Key demographic and clinical findings are collected at registration. Patients are followed up to 12 months in search of incident neurological manifestations. As of August 19, 254 centres from 69 countries and four continents have made requests to join the study.
Search related documents:
Co phrase search for related documents, hyperlinks ordered by date